Dynamics of the gut-liver axis in rats with varying fibrosis severity

被引:14
|
作者
Xiang, Hongyan [1 ]
Liu, Zongyi [1 ]
Xiang, Huanyu [1 ]
Xiang, Dejuan [1 ]
Xiao, Shuang [1 ]
Xiao, Jing [1 ]
Shen, Wei [1 ]
Hu, Peng [1 ]
Ren, Hong [1 ]
Peng, Mingli [1 ]
机构
[1] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Affiliated Hosp 2, Inst Viral Hepatitis,Dept Infect Dis,Minsit Educ, Chongqing 400010, Peoples R China
来源
关键词
gut-liver axis; liver fibrosis; gut microbiota; bile acid; gut barrier; BILE-SALT HYDROLASE; MICROBIOTA; BARRIER; LACTOBACILLUS; CROSSTALK; CIRRHOSIS; DYSBIOSIS; ACIDS; MODEL;
D O I
10.7150/ijbs.69833
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The classic carbon tetrachloride (CCl4)-induced liver injury model is widely used to study the pathogenesis of fibrosis and evaluate anti-fibrosis drugs. Here, we investigated the dynamic changes in the gut microbiota, bile acids (BAs) and the gut barrier over different fibrosis severities in a CCl4-based model. 16S rDNA sequencing demonstrated that the beneficial taxon Lactobacillus was always underrepresented, and pathogens including Escherichia_Shigella, Clostadium_sensu_stacto_1, Colidextribacter, and Lachnospiraceae_UCG_010 were significantly overrepresented across liver fibrosis severities. Gut dysbiosis was more severe at the early stage of liver injury and advanced stage of fibrosis. An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis revealed that with the progress of fibrosis, unconjugated BAs in faeces were significantly decreased and conjugated BAs in serum were significantly increased. The FXR-SHP signalling pathway in the liver and ileum was statistically repressed in the fibrosis groups. Determination of lipopolysaccharide (LPS) and fluorescein isothiocyanate (FITC)-dextran levels in plasma showed that the intestinal barrier remained relatively intact in the advanced fibrosis stage. The advances in knowledge of the gut-liver axis provided by this study yield new insights for application in research and drug evaluation.
引用
收藏
页码:3390 / 3404
页数:15
相关论文
共 50 条
  • [41] Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia
    Fukui, Hiroshi
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (03) : 425 - 442
  • [42] Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist
    Moon, An-Na
    Breyner, Natalia
    Song, Dong-Keun
    Madsen, Martin R. onn
    Kim, Hongbin
    Choi, Keonwoo
    Lee, Yoonsuk
    Namkung, Wan
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [43] Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia
    Hiroshi Fukui
    World Journal of Hepatology, 2015, (03) : 425 - 442
  • [44] Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update
    Fukui, Hiroshi
    GUT AND LIVER, 2021, 15 (05) : 666 - 676
  • [45] The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective
    De Muynck, Kevin
    Vanderborght, Bart
    Van Vlierberghe, Hans
    Devisscher, Lindsey
    CELLS, 2021, 10 (11)
  • [46] Fat, cancer, the gut-liver axis and rare liver diseases
    Berenguer, Marina
    JHEP REPORTS, 2020, 2 (06)
  • [47] The gut-liver axis in liver disease: Pathophysiological basis for therapy
    Albillos, Agustin
    de Gottardi, Andrea
    Rescigno, Maria
    JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 558 - 577
  • [48] Gut-liver axis: Pathophysiological concepts and clinical implications
    Tilg, Herbert
    Adolph, Timon E.
    Trauner, Michael
    CELL METABOLISM, 2022, 34 (11) : 1700 - 1718
  • [49] A gut-liver axis in intestinal stem cell fitness
    Ray, Katrina
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (04) : 218 - 218
  • [50] Intestinal ischemia and the gut-liver axis:: An in vitro model
    Towfigh, S
    Heisler, T
    Rigberg, DA
    Hines, OJ
    Chu, J
    McFadden, DW
    Chandler, C
    JOURNAL OF SURGICAL RESEARCH, 2000, 88 (02) : 160 - 164